Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
Genomic Frontiers | Sangamo Therapeutics advances gene therapy innovations, with partnerships in neurodegenerative diseases and promising results in hemophilia A treatment |
Financial Tightrope | Extended cash runway to Q1 2025, but financial challenges persist. Analyst price targets range from $2 to $10, reflecting mixed market sentiment |
Accelerated Horizons | Explore potential fast-track approval for Fabry disease treatment, positioning Sangamo for earlier market entry and competitive advantage |
Strategic Alliances | Genentech partnership validates technology, provides funding, and opens doors to high-value neurodegenerative disease market, boosting long-term prospects |
Metrics to compare | SGMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSGMOPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −2.3x | −0.6x | |
PEG Ratio | −0.03 | −0.04 | 0.00 | |
Price/Book | 6.3x | 2.5x | 2.6x | |
Price / LTM Sales | 4.7x | 6.0x | 3.1x | |
Upside (Analyst Target) | 335.8% | 590.8% | 51.5% | |
Fair Value Upside | Unlock | −12.2% | 7.6% | Unlock |